Literature DB >> 11892691

Survival analysis using auxiliary variables via multiple imputation, with application to AIDS clinical trial data.

Cheryl L Faucett1, Nathaniel Schenker, Jeremy M G Taylor.   

Abstract

We develop an approach, based on multiple imputation, to using auxiliary variables to recover information from censored observations in survival analysis. We apply the approach to data from an AIDS clinical trial comparing ZDV and placebo, in which CD4 count is the time-dependent auxiliary variable. To facilitate imputation, a joint model is developed for the data, which includes a hierarchical change-point model for CD4 counts and a time-dependent proportional hazards model for the time to AIDS. Markov chain Monte Carlo methods are used to multiply impute event times for censored cases. The augmented data are then analyzed and the results combined using standard multiple-imputation techniques. A comparison of our multiple-imputation approach to simply analyzing the observed data indicates that multiple imputation leads to a small change in the estimated effect of ZDV and smaller estimated standard errors. A sensitivity analysis suggests that the qualitative findings are reproducible under a variety of imputation models. A simulation study indicates that improved efficiency over standard analyses and partial corrections for dependent censoring can result. An issue that arises with our approach, however, is whether the analysis of primary interest and the imputation model are compatible.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11892691     DOI: 10.1111/j.0006-341x.2002.00037.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  13 in total

1.  Random change point model for joint modeling of cognitive decline and dementia.

Authors:  Hélène Jacqmin-Gadda; Daniel Commenges; Jean-François Dartigues
Journal:  Biometrics       Date:  2006-03       Impact factor: 2.571

2.  Joint multiple imputation for longitudinal outcomes and clinical events that truncate longitudinal follow-up.

Authors:  Bo Hu; Liang Li; Tom Greene
Journal:  Stat Med       Date:  2015-07-15       Impact factor: 2.373

Review 3.  Basic concepts and methods for joint models of longitudinal and survival data.

Authors:  Joseph G Ibrahim; Haitao Chu; Liddy M Chen
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

4.  Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials.

Authors:  Danjie Zhang; Ming-Hui Chen; Joseph G Ibrahim; Mark E Boye; Ping Wang; Wei Shen
Journal:  Stat Med       Date:  2014-07-20       Impact factor: 2.373

5.  Estimating the prevalence of atrial fibrillation from a three-class mixture model for repeated diagnoses.

Authors:  Liang Li; Huzhang Mao; Hemant Ishwaran; Jeevanantham Rajeswaran; John Ehrlinger; Eugene H Blackstone
Journal:  Biom J       Date:  2016-12-16       Impact factor: 2.207

6.  A guide to missing data for the pediatric nephrologist.

Authors:  Nicholas G Larkins; Jonathan C Craig; Armando Teixeira-Pinto
Journal:  Pediatr Nephrol       Date:  2018-03-13       Impact factor: 3.714

7.  Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival.

Authors:  Anna S C Conlon; Jeremy M G Taylor; Daniel J Sargent; Greg Yothers
Journal:  Clin Trials       Date:  2011-09-15       Impact factor: 2.486

8.  A shrinkage approach for estimating a treatment effect using intermediate biomarker data in clinical trials.

Authors:  Yun Li; Jeremy M G Taylor; Roderick J A Little
Journal:  Biometrics       Date:  2011-05-31       Impact factor: 2.571

9.  Joint modeling of survival time and longitudinal data with subject-specific changepoints in the covariates.

Authors:  Jean de Dieu Tapsoba; Shen-Ming Lee; C Y Wang
Journal:  Stat Med       Date:  2010-11-05       Impact factor: 2.373

10.  Landmark estimation of survival and treatment effects in observational studies.

Authors:  Layla Parast; Beth Ann Griffin
Journal:  Lifetime Data Anal       Date:  2016-02-15       Impact factor: 1.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.